OncLive

The importance of multidisciplinary care in chronic lymphocytic leukemia and proper patient education on adverse events associated with novel targeted therapies.

Common toxicities associated with novel targeted therapies, such as BTK inhibitors, used to treat chronic lymphocytic leukemia, and recommendations on how to manage with dose adjustments.

Recommendations for using novel targeted therapies to treat chronic lymphocytic leukemia in the frontline setting.

Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center discuss how to manage a 67-year-old woman with chronic lymphocytic leukemia who develops progressive fatigue and night sweats.

Staging criteria used in the diagnosis of chronic lymphocytic leukemia, and recommendations for talking with patients about molecular testing results and goals of therapy.

An overview of tests used to evaluate patients for chronic lymphocytic leukemia and, consequently, inform treatment decisions.

Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center react to the variation in symptoms that patients suspicious of chronic lymphocytic leukemia present with.

Treatment algorithms used in clinical practice by breast oncologists to best approach and subsequently treat patients with HER2-positive metastatic breast cancer.

A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Breast cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Hematologic cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Physicians' Education Resource (PER), a prominent medical education company that specializes in oncology and hematology conferences and programs, is now part of ArcMesa Educators

Links to resource from across the web for brain cancer; includes news briefs, patient education, research and clinical trials

Links to resources from across the web for bone mets; includes award winners and clinical trials.

As cancer-fighting therapies become more targeted, clinicians are looking increasingly toward emerging technologies to help confirm the primary site of a patient's disease.

Michael T. Lewis, PhD, runs a research lab at the Baylor College of Medicine focused on understanding the role of hedgehog signaling in mammary gland development and breast cancer

Nine cancer researchers will be honored along with a US senator at the ASCO annual meeting June 3-7 in Chicago, Illinois.

A guide to internet resources, CMEs, Clinical Trials and much more

Bicalutamide during and after radiation therapy reduced the risk of progression and the risk of metastatic disease in men with a rising prostate-specific antigen

A look at cancer centers, resources, clinical trials, CME and other offerings from across the web

A biomarker test for DNA methylation identified 22 gene sites able to differentiate between melanoma and nonmelanoma lesions